Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ.

Am J Kidney Dis. 2005 Feb;45(2):281-7.

PMID:
15685505
2.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
3.
4.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
5.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
6.

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S48-52. Review.

7.

Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

Ruilope LM.

Am J Hypertens. 1997 Dec;10(12 Pt 2):325S-331S. Review.

PMID:
9438777
8.

[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].

Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.

Ital Heart J Suppl. 2003 Mar;4(3):210-6. Review. Italian.

PMID:
12784755
9.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
10.
11.

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Croom KF, Plosker GL.

Drugs. 2008;68(11):1543-69. Review.

PMID:
18627212
13.

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.

Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ.

Nephrol Dial Transplant. 2005 Jun;20(6):1103-9. Epub 2005 Apr 26. Review.

PMID:
15855214
14.
15.
16.

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.

Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ; Collaborative Study Group.

Kidney Int Suppl. 2004 Nov;(92):S99-101. Review.

PMID:
15485429
17.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

19.

[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].

de Alvaro F.

Nefrologia. 2001;21 Suppl 3:76-82. Review. Spanish. No abstract available.

20.

Ischemic nephropathy in South Dakota: case reports and review.

Natarajan M, Larson C, Zawada ET Jr.

S D J Med. 2004 Sep;57(9):417-22. Review.

PMID:
15481363

Supplemental Content

Support Center